Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases
Caoilfhionn M Connolly, Julie J. Paik(Universitat Autònoma de Barcelona), Jake A. Ruddy(Johns Hopkins University), William A. Werbel(Johns Hopkins University), Jacqueline Garonzik‐Wang(University of Wisconsin–Madison), Robin K. Avery(Johns Hopkins University), Brian J. Boyarsky(Johns Hopkins University), Dorry L. Segev(New York University)
Cited by 71
Related Papers
Foot strike patterns and collision forces in habitually barefoot versus shod runners
|Nature|2010|1.4k
The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials
|American Journal of Transplantation|2017|1k
Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients
|JAMA|2021|1k
Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients
|JAMA|2021|536
Kidney-Failure Risk Projection for the Living Kidney-Donor Candidate
|New England Journal of Medicine|2015|450